EUCTR2004-000963-81-AT进行中（未招募）不适用
A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines
Robapharm AG0 个研究点目标入组 230 人开始时间: 2004年11月10日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Women over 65 years
- •- Prior therapy with anthracyclines
- •- Documented metastatic breast cancer
- •- Karnofsky Performance Status not less than 70%
- •- Presence of at least one measurable lesion according to RECIST criteria
- •- Adequate haematological, hepatic and renal function
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients with life-threatening conditions
- •- Malabsorption syndrome or disease significantly affecting gastro-intestinal function or major resection of the stomach, proximal small bowel or grade not less than 2 dysphagia
- •- Other serious illness or medical condition
研究者
相似试验
进行中（未招募）
1 期
A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclinesEUCTR2004-000963-81-BEPierre Fabre Medicament230
进行中（未招募）
1 期
Randomised phase II trial to compare two first line chemotherapy regimen : oral vinorelbine and cisplatin followed by maintenance therapy with single agent oral vinorelbine and gemcitabine and cisplatin followed by maintenance therapy with single agent gemcitabine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological type.First line locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) patient with squamous histological type.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-ITPIERRE FABRE MEDICAMENT110
进行中（未招募）
1 期
Study evaluating oral vinorelbine and cisplatin followed by oral vinorelbine alone versus gemcitabine and cisplatin followed by gemcitabine alone in patients with a specific type of lung cancerFirst line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological typeMedDRA version: 15.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-ATPierre Fabre Medicament113
进行中（未招募）
1 期
Study evaluating oral vinorelbine and cisplatin followed by oral vinorelbine alone versus gemcitabine and cisplatin followed by gemcitabine alone in patients with a specific type of lung cancerFirst line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological typeMedDRA version: 19.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-PLPierre Fabre Medicament110
进行中（未招募）
1 期
Study evaluating oral vinorelbine and cisplatin followed by oral vinorelbine alone versus gemcitabine and cisplatin followed by gemcitabine alone in patients with a specific type of lung cancerFirst line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients withsquamous histological typeMedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003531-40-ESPierre Fabre Medicament110